- Home
- COE vs MNOV Comparison
COE vs MNOV Comparison
Compare COE & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- MNOV
- Stock Information
- Founded
- COE 2011
- MNOV 2000
- Country
- COE Singapore
- MNOV United States
- Employees
- COE N/A
- MNOV N/A
- Industry
- COE Other Consumer Services
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- COE Real Estate
- MNOV Health Care
- Exchange
- COE Nasdaq
- MNOV Nasdaq
- Market Cap
- COE 91.4M
- MNOV 76.0M
- IPO Year
- COE 2016
- MNOV 2005
- Fundamental
- Price
- COE $14.73
- MNOV $1.45
- Analyst Decision
- COE
- MNOV Strong Buy
- Analyst Count
- COE 0
- MNOV 1
- Target Price
- COE N/A
- MNOV $9.00
- AVG Volume (30 Days)
- COE 11.9K
- MNOV 16.4K
- Earning Date
- COE 06-11-2025
- MNOV 05-08-2025
- Dividend Yield
- COE N/A
- MNOV N/A
- EPS Growth
- COE N/A
- MNOV N/A
- EPS
- COE N/A
- MNOV N/A
- Revenue
- COE $50,692,000.00
- MNOV N/A
- Revenue This Year
- COE N/A
- MNOV N/A
- Revenue Next Year
- COE N/A
- MNOV N/A
- P/E Ratio
- COE N/A
- MNOV N/A
- Revenue Growth
- COE 86.98
- MNOV N/A
- 52 Week Low
- COE $6.10
- MNOV $1.12
- 52 Week High
- COE $25.70
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- COE 32.97
- MNOV 50.85
- Support Level
- COE $13.60
- MNOV $1.36
- Resistance Level
- COE $22.00
- MNOV $1.35
- Average True Range (ATR)
- COE 1.59
- MNOV 0.09
- MACD
- COE -0.58
- MNOV 0.03
- Stochastic Oscillator
- COE 13.45
- MNOV 91.43
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.